FCT EMBRACE MARKS FUJIFILM’S ENTRANCE INTO U.S. CT MARKETPLACE
Fujifilm Medical Systems unveiled its FCT Embrace at the 2018 ASTRO annual meeting in October, marking Fujifilm’s entry into the U.S. CT market. The new system, combined with other market-leading oncology solutions, is designed to provide enhanced and efficient CT simulation with radiotherapy treatment planning capabilities.
Approved by the FDA, the FCT Embrace is the world’s first 85cm wide bore CT imaging unit to perform at 64- or 128-slice configurations, optimizing both oncology and radiology applications.
“With advanced image processing, higher rotational speed, wider detector coverage and greater noise reduction, the FCT Embrace provides exceptional detail for greater clinical confidence,” Rick Banner, senior marketing director, said.
The system is designed to serve oncology care providers such as radiation therapists, who will utilize the easy-to-use touch screen, and radiation oncologists who will experience better image quality with the high slice count options.
According to Fujifilm, when compared to a standard wide bore system, the FCT Embrace offers a clean design and a very small footprint. Powered by , the system provides advanced imaging capabilities on a standardized platform with the widest table top available at 49cm – a feature accommodating bariatric patients weighing up to 660 lbs.
“For radiation therapy practitioners and their patients, the FCT Embrace has an intelligent design that optimally matches the rotational arc of the linear accelerator, offering easy and precise positioning options for simulation, with the benefit of high-resolution images from a 64-slice and above clinical system at low dose levels,” Banner said. VTN